Previous Section
New Developments in Graves' Disease
Newer, less invasive surgical procedures are being developed for the treatment of Graves' ophthalmopathy.
Researchers are studying the long-term safety of orbital radiotherapy for the treatment of Graves' ophthalmopathy.
Research is ongoing to identify the optimal management strategies for Graves' disease in children.
Research is ongoing to identify the optimal management strategies for Graves' disease during pregnancy.
Researchers are studying the impact of smoking on the response to treatment in patients with Graves' ophthalmopathy.
Botulinum A toxin injection is being investigated for the treatment of restrictive myopathy of thyroid-related orbitopathy.
New drugs being investigated for the treatment of Graves' disease include:
- Intravenous immunoglobulins
- Antioxidants (vitamins C and E; beta-carotene; selenium)
- Cytokine antagonists
- Colchicine
- Methotrexate for Graves' ophthalmopathy
- Short or long-acting sandostatin analogues for Graves' ophthalmopathy
Although the cause of Graves' disease is currently unknown, research is ongoing to identify immunological and genetic components that may play a role in the development of this condition. Research in these areas is of critical importance since it may lead to prevention and/or improved methods of treatment for Graves' disease.
Information regarding ongoing clinical trials in your area can be obtained at the Clinical Trials Listing Service at http://www.centerwatch.com
